Waverley Expands UK Cancer Portfolio

Marketing Authorizations Obtained For Erlotinib Tablets

02 Jan 2020

• By Aidan Fry

Having made its entry into the UK oncology generics market late last year with capecitabine and temozolomide, Canada’s Waverley Pharma now has clearance to add erlotinib tablets to its portfolio.

Erlotinib — Waverley Pharma is expanding its range of oncology drugs in the UK • Source: Shutterstock

Small-molecule oncology generics specialist Waverley Pharmaceuticals has expanded its cancer portfolio in the UK by securing approval for a generic version of Roche’s Tarceva (erlotinib) oral treatment for non-small cell lung cancer and pancreatic cancer.

The marketing authorizations granted by the UK’s Medicines and Healthcare products Regulatory Agency to Waverley’s wholly-owned Irish subsidiary cover 25mg,...